Mereo BioPharma Group plc
MREO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.58 | -0.08 | 0.36 | 0.11 |
| FCF Yield | -1.77% | -2.37% | -1.73% | -1.19% |
| EV / EBITDA | -26.43 | -25.99 | -69.43 | -38.93 |
| Quality | ||||
| ROIC | -18.86% | -18.19% | -23.71% | -11.60% |
| Gross Margin | 73.60% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.04 | 0.52 | 0.65 | 1.34 |
| Growth | ||||
| Revenue 3-Year CAGR | -67.01% | -67.12% | -100.00% | -100.00% |
| Free Cash Flow Growth | 8.36% | 11.37% | -25.28% | 4.86% |
| Safety | ||||
| Net Debt / EBITDA | 3.88 | 5.51 | 9.17 | 5.14 |
| Interest Coverage | -437.46 | -62.23 | -40.73 | -26.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -101.45 | -970.94 | 274.84 | -552.21 |